Doxorubicin: nanotechnological overviews from bench to bedside

CAGEL M.; GROTZ E.; BERNABEU E.; MORETTON M.A.; CHIAPPETTA D.A.

DRUG DISCOVERY TODAY

ELSEVIER SCI LTD

Lugar: Amsterdam; Año: 2017 vol. 22 p. 270 - 281

1359-6446

Doxorubicin (DOX) is considered one of the most effectivechemotherapeutic agents, used as a first-line drug in numerous types ofcancer. Nevertheless, it exhibits serious adverse effects, such as lethalcardiotoxicity and dose-limiting myelosuppression. In this review, wefocus on the description and the clinical benefits of different DOX-loadednanotechnological platforms, not only those commercially available butalso the ones that are currently in clinical phases, such as liposomes,polymeric nanoparticles, polymer?drug conjugates, polymeric micellesand ligand-based DOX-loaded nanoformulations. Although some DOXbasednanoproducts are currently being used in the clinical field, it is clearthat further research is necessary to achieve improvements in cancertherapeutics.